Controlled Human Infection Model
Cross-source consensus on Controlled Human Infection Model from 1 sources and 4 claims.
1 sources · 4 claims
Risks & contraindications
Comparisons
Background
Where it comes from
Highlighted claims
- UNC-CH is the only institution currently operating the gonorrhea CHIM platform. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol
- The gonorrhea CHIM was developed at UNC-CH and Walter Reed in the late 1980s and early 1990s. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol
- Over 33 years, 257 male volunteers have been challenged without serious or irreversible adverse events. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol
- The CHIM uses a standardized controlled exposure that can detect 30% vaccine efficacy with far fewer participants than natural exposure studies. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol